<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590183</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00006761-M2020059</org_study_id>
    <nct_id>NCT04590183</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Safety of FK-506 for the Treatment of Posner-Schlossman Syndrome</brief_title>
  <official_title>Peking University Third Hospital Medical Science Research Ethics Committee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness and safety of tacrolimus eye drops (FK-506) in the treatment of&#xD;
      Posner-Schlossman Syndrome. It is expected to collect 30 patients with PSS who are in the&#xD;
      Ophthalmology Department of Peking University Third Hospital. The included PSS patients were&#xD;
      divided into experimental group and control group using simple randomization method. Among&#xD;
      them, the experimental group was treated with FK-506 twice a day, and the control group was&#xD;
      treated with prednisolone acetate ophthalmic suspension 1% 4 times a day.&#xD;
&#xD;
      For all PSS patients whose intraocular pressure is higher than 30mmHg, also add brinzolamide&#xD;
      eye drops 3 times a day. Best corrected visual acuity, Goldmann intraocular pressure,&#xD;
      anterior section photographs, corneal endothelial cellsï¼Œcorneal confocal microscope,&#xD;
      Heidelberg retinal nerve analysis, Octopus visual field were examined on baseline and 1 week,&#xD;
      2 weeks, 3 weeks, 4 weeks after the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Silt-lamp examination of the cornea</measure>
    <time_frame>1 week after the treatment</time_frame>
    <description>KP numbers after the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Silt-lamp examination of the cornea</measure>
    <time_frame>2 weeks after the treatment</time_frame>
    <description>KP numbers after the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Silt-lamp examination of the cornea</measure>
    <time_frame>3 weeks after the treatment</time_frame>
    <description>KP numbers after the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Silt-lamp examination of the cornea</measure>
    <time_frame>4 weeks after the treatment</time_frame>
    <description>KP numbers after the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Goldmann ophthalmotonometer examination of intra-ocular pressure</measure>
    <time_frame>1 week after the treatment</time_frame>
    <description>change of intra-ocular pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Goldmann ophthalmotonometer examination of intra-ocular pressure</measure>
    <time_frame>2 weeks after the treatment</time_frame>
    <description>change of intra-ocular pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Goldmann ophthalmotonometer examination of intra-ocular pressure</measure>
    <time_frame>3 weeks after the treatment</time_frame>
    <description>change of intra-ocular pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Goldmann ophthalmotonometer examination of intra-ocular pressure</measure>
    <time_frame>4 weeks after the treatment</time_frame>
    <description>change of intra-ocular pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Posner Schlossman Syndrome</condition>
  <arm_group>
    <arm_group_label>The experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK-506 (Drug)</intervention_name>
    <description>Twice a day</description>
    <arm_group_label>The experimental group</arm_group_label>
    <other_name>Tacrolimus eye drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 1% Oph Susp</intervention_name>
    <description>Four times a day</description>
    <arm_group_label>The control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Clinical diagnosis of PSS Must be able to communicate with doctor and understand this&#xD;
        study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Fuchs syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun Zhang, PHD,MD</last_name>
    <role>Study Director</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tingting Gao, PHD</last_name>
    <phone>0086-13795176872</phone>
    <email>gaotingting8139@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hosipital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pro. Zhang, PHD, MD</last_name>
      <phone>0086-186-0103-1059</phone>
      <email>zhangc1@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Chun Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Posner Schlossman Syndrome</keyword>
  <keyword>FK-506</keyword>
  <keyword>effectiveness</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

